New drug delivery method targeting prostate cancer cells
Tumor-Activated Dual Payload-Drug Conjugates
This study is testing a new drug that aims to better treat prostate cancer by delivering two types of chemotherapy directly to the tumor, which could help improve outcomes for men with advanced prostate cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington State University NIH-funded |
| Lab location | 1 site (Pullman, United States) |
| Project ID | NIH-10947537 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of drug that targets prostate cancer cells by using a specific biomarker called prostate specific membrane antigen (PSMA). The approach involves creating a dual drug conjugate that can deliver two different chemotherapy agents directly to the tumor site, potentially improving treatment effectiveness. By activating these drugs at the tumor location, the goal is to enhance the therapeutic impact and provide better outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). This innovative strategy aims to offer new treatment options that could extend survival and improve the quality of life for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who have PSMA-positive tumors.
Not a fit: Patients with early-stage prostate cancer or those without PSMA-positive tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with PSMA-targeted therapies, indicating potential for success with this novel dual drug approach.
Where this research is happening
Pullman, United States
- Washington State University — Pullman, United States (Active)
Researchers
- Principal investigator: Berkman, Clifford — Washington State University
- Study coordinator: Berkman, Clifford
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.